June 30, 2022Annals of Pharmacotherapy

Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol

View Full Paper

Ask AI

Bookmark

Authors

ESEssie SamuelPhiladelphia College of Osteopathic Medicine MWMaya WatfordPhiladelphia College of Osteopathic Medicine UEUgochukwu EgolumGeorgia Department of Education

Abstract

Inclisiran is an effective and safe medication for lowering LDL-C levels. Additional data regarding efficacy on cardiovascular outcomes and long-term safety profile with inclisiran are needed.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Samuel et al. (2022) studied this question.

synapsesocial.com/papers/69dcffbde3a90a2e2f13364f https://doi.org/10.1177/10600280221105169

View Full Paper

Ask AI

Bookmark

Abstract

Inclisiran is an effective and safe medication for lowering LDL-C levels. Additional data regarding efficacy on cardiovascular outcomes and long-term safety profile with inclisiran are needed.

Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol

Abstract

Discussion

Cite This Study

Inclisiran: A First-in-Class siRNA Therapy for Lowering Low-Density Lipoprotein Cholesterol

Abstract

Discussion

Cite This Study

Also Consider

Also Consider